The abstract is read at the publisher; the summary is JClub's.
Human iPSC-derived cardiomyocytes from women with persistent cancer therapy-related cardiac dysfunction show transcriptomic responses to doxorubicin and trastuzumab that cluster more tightly than chance (P = 0.04).
- Why it matters: CTRCD after anthracycline and trastuzumab affects only some patients, and it is unclear whether persistence reflects an intrinsic cardiomyocyte program.
- What they did: iPSC-CMs from 23 women (5 no, 11 reversible, 7 persistent CTRCD) were exposed to 7 drug regimens, yielding 161 transcriptomic profiles analyzed by singular value decomposition and pathway enrichment, with reliability tested by 100 label permutations and leave-one-patient-out downsampling.
- The result: Persistent CTRCD is linked to stronger induction or reduced repression of natriuretic peptides and cardiac troponins, lower natriuretic peptide receptor signaling, and distinct contraction, calcium handling, cytoskeletal, and glycolytic pathway signatures.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.